Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Torcetrapib's Silver Lining

This article was originally published in RPM Report

Executive Summary

What looks like bad news for the future of the CEPT inhibitor class of HDL-raising drugs may have a hidden silver lining for pharmaceutical companies interested in advancing the use of imaging as a clinical trial endpoint.

You may also be interested in...



Imaging Standards for Clinical Trials: A Picture Worth 1,000 Guidance Documents

FDA is signaling its commitment to validating surrogate endpoints by agreeing to set standards on the use of imaging techniques in clinical trials. But industry will have to wait for a definitive answer: the document isn't slated for released until 2011.

Imaging Standards for Clinical Trials: A Picture Worth 1,000 Guidance Documents

FDA is signaling its commitment to validating surrogate endpoints by agreeing to set standards on the use of imaging techniques in clinical trials. But industry will have to wait for a definitive answer: the document isn't slated for released until 2011.

Abbott Rides High After Torcetrapib Collapse: Is Everything Old New Again?

The end of torcetrapib was bad news for Pfizer, and could be a death knell for the entire CETP inhibitor class. But it also makes Abbott's acquisition of Kos look prescient. Wall Street is taking notice.

Topics

Related Companies

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel